NASDAQ: CELC - Celcuity Inc.

半年間の収益性: -14.52%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Celcuity Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

さらに詳しく
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2017-09-20
ISIN US15102K1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.celcuity.com
Цена ао 17.52
1日あたりの価格変動: +5.81% (13.08)
週ごとの価格変動: +11.08% (12.46)
月ごとの料金変更: +7.7% (12.85)
3ヶ月間の価格変動: -3.89% (14.4)
半年間の価格変動: -14.52% (16.19)
年間の価格変動: -5.01% (14.57)
3年間の価格推移: +12.34% (12.32)
5年間の価格推移: +38.54% (9.99)
10年間の価格推移: 0% (13.84)
年初からの価格変動: -5.46% (14.64)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 2.54 6
P/E 0 0
EV/EBITDA -5.47 0
合計: 3

効率

名前 意味 学年
ROA, % -33.35 0
ROE, % -45.63 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.5632 10
合計: 8

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 687.97 10
収益性 EPS, % 292.34 10
合計: 8
さらに詳しく

機関 音量 共有, %
Morgan Stanley 2195179 7.21
Soleus Capital Management, L.P. 2179481 7.16
VR Adviser, LLC 1885538 6.19
COMMODORE CAPITAL LP 1754704 5.76
Perceptive Advisors LLC 1481300 4.86
NEA Management Company, LLC 1250001 4.1
Blackrock Inc. 1050391 3.45
Vanguard Group Inc 820776 2.7
CapTrust Financial Advisors 544835 1.79
Baker Brothers Advisors, LLC 535478 1.76

ETF 共有, % 年間の利益率, % 配当金, %
Jacob Forward ETF 0.85997 43.03 0.15284
Virtus LifeSci Biotech Clinical Trials ETF 0.76638 63.04 0.33
iShares Micro-Cap ETF 0.1014 17.09 1.54048
Vanguard Russell 2000 Growth ETF 0.03 23.05 0.60264
iShares Russell 2000 Growth ETF 0.02744 38.04 0.6026
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
iShares Morningstar Small-Cap Growth ETF 0.00891 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.00891 587.89 0.72598
ProShares UltraPro Russell2000 0.0075 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.00435 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00435 391.25 1.60498
Humankind US Stock ETF 0.00221 18.81 1.99919
ProShares Hedge Replication ETF 0.00212 5.92 1.47892
iShares Russell 3000 ETF 0.00079 24.83 1.43482
Vanguard Russell 3000 ETF 0 31.87 1.43817



スーパーバイザー 役職 支払い 生年
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO 478.12k 1962 (63 年)
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Secretary & Director 389.55k 1962 (63 年)
Ms. Vicky Hahne Chief Financial Officer 281.59k 1966 (59 年)
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of R&D N/A 1955 (70 年)
Ms. Sheri Smith Acting Head of Clinical Operations N/A
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer N/A
Mr. Eldon C. Mayer III, M.B.A. Chief Commercial Officer N/A 1961 (64 年)
Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. Senior Vice President of Clinical Development

住所: United States, Minneapolis. MN, 16305–36th Avenue North - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.celcuity.com